SOPHiA GENETICS SA SOPH
- Market cap
- $703.2M
- P/E
- 0.0×
Follow SOPH
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 11.71 | 1.69 | 1.85 | 2.70 | 2.58 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 19.80 | 15.83 | 5.77 | 7.37 | 5.30 |
High Price
|
|||
| — | — | — | — | 462 | 518 | 466 | 449 | 423 | 415 |
Employees
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | 25 | 28 | 40 | 48 | 62 | 65 | 77 |
Revenue
|
|||
| — | — | — | 70.30% | 62.29% | 62.35% | 65.71% | 68.80% | 67.42% | 67.40% |
Gross Margin
|
|||
| — | — | — | (34) | (41) | (74) | (88) | (78) | (61) | (77) |
EBT
|
|||
| — | — | — | (132.60%) | (145.16%) | (181.72%) | (184.16%) | (125.85%) | (94.01%) | (100.28%) |
EBT Margin
|
|||
| — | 0 | — | (34) | (41) | (74) | (88) | (78) | (61) | (77) |
Net Income
|
|||
| — | — | — | 2 | 2 | 4 | 6 | 8 | 9 | 10 |
Depreciation
|
|||
| — | — | — | 0.67 | 0.67 | 0.73 | 0.74 | 0.96 | 0.99 | 1.14 |
Revenue/Sh
|
|||
| — | — | — | (0.90) | (0.93) | (1.33) | (1.36) | (1.22) | (0.95) | (1.17) |
Earnings/Sh
|
|||
| — | — | — | (0.84) | (0.75) | (1.05) | (1.09) | (0.75) | (0.67) | (0.53) |
Cash Flow/Sh
|
|||
| — | — | — | (0.08) | (0.02) | (0.05) | (0.07) | (0.03) | (0.01) | (0.01) |
Capex/Sh
|
|||
| — | — | — | (0.92) | (0.77) | (1.10) | (1.16) | (0.78) | (0.68) | (0.54) |
Free CF/Sh
|
|||
| — | — | — | 0.59 | 2.37 | 4.98 | 3.12 | 2.34 | 1.46 | 0.70 |
Book Value/Sh
|
|||
| — | — | — | 38 | 42 | 55 | 64 | 65 | 66 | 68 |
Shares
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | 24.00 | 24.00 | 19.28 | 3.03 | 5.01 | 3.11 | 4.08 |
PS Ratio
|
|||
| — | — | — | 11.53 | 11.53 | 2.83 | 0.72 | 2.07 | 2.10 | 6.69 |
PB Ratio
|
|||
| — | — | — | 22.22 | 22.22 | 13.04 | (0.37) | 3.32 | 2.13 | 3.83 |
EV/Sales
|
|||
| — | — | — | (15.90) | (15.90) | (8.68) | 0.24 | (4.12) | (3.09) | (8.07) |
EV/FCF
|
|||
| — | — | — | (32) | (32) | (58) | (70) | (49) | (45) | (36) |
Op' Cash Flow
|
|||
| — | — | — | (3) | (1) | (3) | (5) | (2) | 0 | (1) |
Capex
|
|||
| — | — | — | (35) | (32) | (61) | (75) | (50) | (45) | (37) |
FCF
|
|||
| — | — | — | 15 | 88 | 254 | 169 | 112 | 73 | 49 |
Working Cap'
|
|||
| — | — | — | 4 | 3 | 13 | 17 | — | 13 | 48 |
Total Debt
|
|||
| — | — | — | (15) | (94) | (252) | (162) | (123) | (67) | (23) |
Net Debt
|
|||
| — | — | — | 22 | 101 | 275 | 200 | 151 | 96 | 47 |
Sh' Equity
|
|||
| — | — | — | (130.83%) | (42.81%) | (32.58%) | (31.01%) | (35.10%) | (34.58%) | (49.63%) |
ROA
|
|||
| — | — | — | (263.58%) | (359.77%) | (193.09%) | (143.46%) | (165.89%) | (141.03%) | (180.23%) |
ROIC
|
|||
| — | — | — | (55.05%) | (64.09%) | (39.20%) | (36.78%) | (44.93%) | (50.41%) | (110.00%) |
ROE
|
|||
SOPHiA GENETICS SA peers in Health Information Services
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| MDRX Veradigm Inc. | $654.5M | 0.0× | Compare |
| PHR Phreesia, Inc. | $620.7M | 59.7× | Compare |
| WEAV Weave Communications, Inc. | $587.3M | 0.0× | Compare |
| HSTM HealthStream, Inc. | $883.3M | 40.5× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NRC National Research Corporation | $450.1M | 78.3× | Compare |
| TDOC Teladoc Health, Inc. | $1.1B | 0.0× | Compare |
| GDRX GoodRx Holdings, Inc. | $1.2B | 62.5× | Compare |
| OMDA Omada Health, Inc. | $1.2B | 281× | Compare |
SOPHiA GENETICS SA (SOPH) key facts
- SOPHiA GENETICS SA (SOPH) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
- SOPHiA GENETICS SA’s revenue for fiscal 2025 (year ended December 2025) was $77.3 million, up 18.6% from fiscal 2024.
- SOPHiA GENETICS SA reported a net loss of $77.5 million, or a loss of $1.17 per share, for fiscal 2025.
- As of September 25, 2026, SOPH traded at $8.34, a market capitalization of $703.2 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 7.1× sales.
- Return on equity was −110.0% and debt-to-equity 0.58.
SOPHiA GENETICS SA (SOPH) Latest News
11 Aug
SOPHiA GENETICS SA (SOPH) released its Q2 2026 earnings call transcript covering quarterly results and business updates. Earnings call transcripts disclose financial performance and guidance that can materially shift investor views and stock trajectory.
8 Aug
AstraZeneca signs two cancer diagnostics deals to widen patient access. Deals may indirectly boost SOPHiA GENETICS exposure in oncology testing.
5 Aug
SOPHiA GENETICS partners with AstraZeneca to advance oncology diagnostics. Partnership with AstraZeneca boosts SOPHiA GENETICS oncology reach and growth prospects.
SOPHiA GENETICS SA partners with AstraZeneca to advance oncology diagnostics. Partnership with AstraZeneca strengthens SOPHiA GENETICS oncology diagnostics position and growth prospects.
4 Aug
SOPH reported record revenue growth during its Q2 2026 earnings call. Record revenue growth signals strong financial performance that can significantly lift future trajectory and investor sentiment.
SOPHiA GENETICS enters collaboration to develop companion diagnostics for precision oncology therapies. Collaboration targets core oncology diagnostics business and opens new partnership-driven revenue paths.
SOPHiA GENETICS SA enters collaboration to develop companion diagnostics for precision oncology therapies. Collaboration targets companion diagnostics development expanding SOPHiA GENETICS oncology market position.
SOPHiA GENETICS enters collaboration to develop companion diagnostics for precision oncology therapies. Collaboration advances core precision diagnostics capabilities and expands oncology market positioning.
SOPHiA GENETICS SA presented Q2 financial results, operational metrics and strategic updates in its earnings call. Q2 earnings details can moderately affect the company's stock performance and future outlook.
SOPHiA GENETICS SA reported second quarter 2026 financial results. Quarterly results deliver updated financial metrics that influence valuation and near-term investor sentiment.
19 Jun
SOPHiA GENETICS SA closed its $57.5 million public offering of ordinary shares after full exercise of the underwriters' option to buy additional shares. The completed $57.5 million share offering directly augments cash reserves and supports operational runway.
16 Jun
SOPHiA GENETICS SA prices $50 million public offering of ordinary shares. Public share offering raises capital while diluting shareholders and pressuring near-term stock performance.
SOPHiA GENETICS SA announced a proposed public offering of ordinary shares. Proposed share offering introduces dilution risk that can pressure stock price and alter capital structure.
10 Jun
SOPHiA GENETICS SA confirms leadership transition ahead of 2026 Annual General Meeting. Leadership transition may alter company strategy and affect market perception.
4 Jun
SOPHiA GENETICS SA signs strategic collaboration MOU with leading global cancer center to advance precision oncology solutions. MOU with major cancer center expands SOPHiA GENETICS oncology reach and adoption potential.
13 May
Synnovis and SOPHiA GENETICS partner to deliver blood-based cancer testing to patients across the U.K., leveraging SOPHiA's AI-powered platform for nationwide clinical access. Strategic partnership with Synnovis enables SOPHiA GENETICS to expand blood-based cancer testing into the U.K. market, enhancing revenue potential and competitive positioning.
Synnovis and SOPHiA GENETICS partner to deliver blood-based cancer testing to patients across the UK. Strategic partnership with Synnovis expands SOPHiA GENETICS' cancer testing services nationwide in the UK, enhancing market presence and growth prospects.
5 May
SOPHiA GENETICS S.A. released Q1 2026 earnings call summary highlighting financial results, operational progress, and forward guidance. Q1 2026 earnings call summary discloses financial performance and strategic updates poised to significantly sway SOPH's market trajectory and investor sentiment.
SOPHiA Genetics (SOPH) released Q1 2026 earnings call transcript detailing quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses financial performance and strategic outlook capable of significantly shifting investor sentiment and stock trajectory.
SOPHiA GENETICS reported first quarter 2026 financial results, highlighting key revenue figures, growth metrics, and operational updates. Quarterly earnings reports significantly influence financial performance, stock valuation, and investor sentiment.
SOPHiA GENETICS SA (SOPH) released Q1 earnings call highlights detailing financial results, operational updates, and strategic outlook. Q1 earnings highlights offer moderate insights into financial health and operations, influencing investor sentiment without transformative shifts.
26 Apr
Analysts issue new fair value targets for SOPHiA GENETICS (NasdaqGS:SOPH), shifting the company's investment narrative. New fair value targets from analysts signal a moderately noticeable shift in investor sentiment and valuation expectations for SOPHiA GENETICS.
16 Apr
Mount Sinai Health System and SOPHiA GENETICS announced a collaboration to advance precision cancer care, unveiled at AACR 2026. Partnership with Mount Sinai Health System strengthens SOPHiA GENETICS' precision oncology platform and market validation.
Mount Sinai Health System and SOPHiA GENETICS SA (SOPH) announced a collaboration to advance precision cancer care, highlighted from AACR 2026. Partnership with Mount Sinai bolsters SOPHiA GENETICS' precision oncology capabilities and market positioning.
Mount Sinai Health System and SOPHiA GENETICS SA (SOPH) announce collaboration to advance precision cancer care, revealed from AACR 2026. Collaboration with Mount Sinai bolsters SOPHiA GENETICS' precision oncology leadership and could significantly enhance revenue prospects and investor sentiment.
7 Apr
SOPHiA GENETICS SA's TEM Data and Applications Arm reports robust growth fueled by surging demand for AI-driven analytics, expanded partnerships, and advancements in precision oncology data solutions. Robust growth in TEM arm highlights strong product momentum and market adoption, poised to boost revenue and competitive edge significantly.
27 Mar
SOPHiA GENETICS (SOPH) narrative shifts as analysts recalibrate growth projections and valuation assumptions amid changing expectations. Recalibrated growth and valuation assumptions represent a significant shift in investor sentiment and SOPH's market trajectory.
4 Mar
SOPHiA GENETICS SA (SOPH) reported strong revenue growth and strategic advancements in Q4 2025 earnings call highlights. Strong revenue growth and strategic developments indicate significant positive influence on SOPH's financial trajectory and investor sentiment.
3 Mar
SOPHiA GENETICS SA (SOPH) released Q4 earnings call highlights covering financial results, operational updates, and forward-looking guidance. Q4 earnings highlights disclose financial performance and strategic initiatives poised to significantly shape SOPH's future trajectory and market position.
SOPHiA GENETICS S.A. released Q4 2025 earnings call summary detailing financial results, operational highlights, and forward-looking guidance. Q4 earnings call summary discloses key financial metrics and strategic updates with potential to significantly sway investor sentiment and stock trajectory.